Show simple item record

dc.contributor.authorAbbott, JR
dc.contributor.authorPatel, PA
dc.contributor.authorHowes, JE
dc.contributor.authorAkan, DT
dc.contributor.authorKennedy, JP
dc.contributor.authorBurns, MC
dc.contributor.authorBrowning, CF
dc.contributor.authorSun, Q
dc.contributor.authorRossanese, OW
dc.contributor.authorPhan, J
dc.contributor.authorWaterson, AG
dc.contributor.authorFesik, SW
dc.date.accessioned2018-11-14T09:25:46Z
dc.date.issued2018-09-13
dc.identifier.citationACS medicinal chemistry letters, 2018, 9 (9), pp. 941 - 946
dc.identifier.issn1948-5875
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2926
dc.identifier.eissn1948-5875
dc.identifier.doi10.1021/acsmedchemlett.8b00296
dc.description.abstractProteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.
dc.formatElectronic-eCollection
dc.format.extent941 - 946
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleDiscovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.
dc.typeJournal Article
dcterms.dateAccepted2018-08-08
rioxxterms.versionofrecord10.1021/acsmedchemlett.8b00296
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfACS medicinal chemistry letters
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Evaluation and Molecular Therapeutics
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamTarget Evaluation and Molecular Therapeutics
dc.contributor.icrauthorRossanese, Olivia


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record